OpenAlex
PricingAboutJobs
Log inGet started
Work

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

HTML

Year: 2015
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Annals of Oncology
DOI: 10.1093/annonc/mdv213
Authors: D. Mavroudis, E. Saloustros, N. Malamos, S. Kakolyris, I. Boukovinas, P. Papakotoulas, N. Kentepozidis, N. Ziras, V. Georgoulias
Institutions: University Hospital of Heraklion, The General Hospital of Heraklion "Venizeleio-Pananio", General-Maternity District Hospital Helena Venizelou, University Hospital of Alexandroupolis, Theageneio General Hospital, Hellenic Airforce General Hospital, Metaxa Hospital, University of Crete
Language: English

Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: HER2-positive breast cancer, adjuvant trastuzumab, dose-dense chemotherapy, docetaxel, FEC chemotherapy, granulocyte colony-stimulating factor, disease-free survival, non-inferiority, cardiotoxicity, axillary lymph node metastasis, early breast cancer
SDG: Good health and well-being

Open Access status: bronze

Funders: Kaiser Permanente, National Comprehensive Cancer Network
OpenAlex ID: W2171277704
FWCI: 6.772
Cites: 22
Cited by: 179
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security